IL6 and rheumatoid arthritis: The blockade of IL-6-mediated signaling by Tocilizumab, a humanized IgG1 monoclonal antibody (mAb) (117), results in a significant enhancement of total Treg numbers in the peripheral blood of RA patients and correlates with disease remission (113).